



CASE LD0318 NP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Maureen S. Gibbons
Type or print name

Maureen S. Gibbons
Signature

February 5, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

CARBONI ET AL.

APPLICATION NO: 10/676,214

FILED: OCTOBER 1, 2003

FOR: SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING
CANCER

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3453




Maureen S. Gibbons
Attorney for Applicants
Reg. No. 44,121

Date: February 5, 2004

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)


 ATTY. DOCKET NO.
LD0318 NP
APPLICATION NO.
10/676,214
APPLICANT
CARBONI ET AL.
FILING DATE
OCTOBER 1, 2003

Group

U.S. PATENT APPLICATION DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	U.S. Patent Application No. 10/677,067 (BMS Docket No. 10047NP)	Filed 10/1/03	Carboni et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AH	WO 02/053596	7/11/02	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AI						<input type="checkbox"/>	<input type="checkbox"/>
	AJ						<input type="checkbox"/>	<input type="checkbox"/>
	AK						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AL	Camirand, A., et al., "Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells", Med. Sci. Monit., Vol. 8, No. 12, pp. BR521-526 (2002)
	AM	Lu, D., et al., "Simultaneous Blockade of Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor Signaling Pathways in Cancer Cells with a Fully Recombinant Bispecific Antibody", The Journal of Biological Chemistry, Vol. 279, No. 4, pp. 2856-2865 (2004)
	AN	Lu, Y., et al., "Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)", Journal of the National Cancer Institute, Vol. 92, No. 24, pp. 1852-1857 (2001)
	AO	Normanno, N., et al., "Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth", Annals of Oncology, Vol. 13, pp. 65-72 (2002)
	AP	Werner, H., et al., "The IGF1 Receptor Gene: A Molecular Target for Disrupted Transcription Factors", Genes, Chromosomes & Cancer, Vol. 36, pp. 113-120 (2003)
	AQ	

EXAMINER

DATE CONSIDERED